NOTCH1 and acute lymphoblastic leukemia: The safety and tolerability of anti-NOTCH1 OMP-52M51 antibody have been evaluated in clinical trials for refractory solid tumors (NCT01778439) [75] and relapsed/refractory lymphoid malignancies, including T-ALL (NCT01703572) [76].